Vabicaserin
id:
vabicaserin-319-448646
title:
Vabicaserin
text:
Vabicaserin (codenamed SCA-136) was a novel antipsychotic and anorectic under development by Wyeth. As of 2010 it is no longer in clinical trials for the treatment of psychosis. It was also under investigation as an antidepressant but this indication appears to have been dropped as well. Vabicaserin acts as a selective 5-HT2C receptor full agonist (Ki = 3 nM; EC50 = 8 nM; IA = 100% (relative to 5-HT)) and 5-HT2B receptor antagonist (IC50 = 29 nM). It is also a very weak antagonist at the 5-HT2A
brand slug:
wiki
category slug:
encyclopedia
description:
Chemical compound
original url:
https://en.wikipedia.org/wiki/Vabicaserin
date created:
date modified:
2024-01-06T06:39:58Z
main entity:
{"identifier":"Q7907856","url":"https://www.wikidata.org/entity/Q7907856"}
image:
{"content_url":"https://upload.wikimedia.org/wikipedia/commons/4/47/Vabicaserin.svg","width":512,"height":622}
fields total:
13
integrity:
15